Development of chitosan/heparin nanoparticle-encapsulated cytolethal distending toxin for gastric cancer therapy

Cheng Kuo Lai, Yu Luen Lu, Jer Tsong Hsieh, Shih Chang Tsai, Chun Lung Feng, Yuh Shyan Tsai, Pei Ching Tsai, Hong Lin Su, Yu Hsin Lin, Chih Ho Lai

研究成果: Article同行評審

23 引文 斯高帕斯(Scopus)


Aim: The aim of this work was to develop pH-responsive nanoparticles encapsulating CdtB and to demonstrate that these particles represent a potential therapeutic agent for gastric cancer. Materials & methods: Chitosan/heparin nanoparticle-encapsulated CdtB was prepared and the delivery efficiency was monitored by confocal laser scanning microscopy. The molecular basis of the nanoparticle-encapsulated CdtB-mediated p53 activation pathway was explored by immunoblot analysis. Antitumoral activities were investigated by analyzing the cell cycle and apoptosis. Results: Chitosan/heparin nanoparticle-encapsulated CdtB preferentially inhibited the proliferation of cells derived from gastric cancer, but not in primary gastric epithelial cells. Treatment of cells with nanoparticle-encapsulated CdtB enhanced cell-cycle arrest at G2/M, followed by apoptosis. Moreover, our data showed that the mechanism for nanoparticle- encapsulated CdtB-induced cell death was mediated by ATM-dependent DNA damage checkpoint responses. Conclusion: These findings indicate that chitosan/heparin nanoparticle-encapsulated CdtB could represent a new CdtB delivery strategy for the treatment of gastric cancer. Original submitted 8 May 2012; Revised submitted 5 February 201.

頁(從 - 到)803-817
出版狀態Published - 2014 6月

All Science Journal Classification (ASJC) codes

  • 生物工程
  • 發展
  • 生物醫學工程
  • 一般材料科學
  • 醫藥(雜項)


深入研究「Development of chitosan/heparin nanoparticle-encapsulated cytolethal distending toxin for gastric cancer therapy」主題。共同形成了獨特的指紋。